Omicron breakthrough infection in a kidney‐transplant patient given pre‐exposition casirivimab and imdevimab monoclonal antibodies

Kamar, Nassim; Gouin, Anna; Izopet, Jacques

doi:10.1111/tid.13803

Cited by 6 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preexposure prophylaxis with casirivimab-imdevimab was not authorized under EUA in the United States, but in France was authorized by the National French Health Authority. 51 , 52 In this context, Dimeglio et al 51 reported on 182 SOT recipients who had low or undetectable antibody responses to vaccines, and who received 2 doses of casirivimab/imdevimab 1 mo apart as preexposure prophylaxis during the Delta variant surge. This was highly successful, as no patient who received this preexposure prophylaxis developed COVID-19, whereas 13 of 296 (4.4%) of those who did not receive casirivimab/imdevimab developed COVID, of whom 3 had severe disease and 1 died.…”

Section: Monoclonal Antibodies For Prophylaxismentioning

confidence: 99%

“…This was highly successful, as no patient who received this preexposure prophylaxis developed COVID-19, whereas 13 of 296 (4.4%) of those who did not receive casirivimab/imdevimab developed COVID, of whom 3 had severe disease and 1 died. 51 More recently, Kamar et al 52 reported 1 patient (out of 436 who had received casirivimab/imdevimab for preexposure prophylaxis) who had breakthrough infection with the Omicron variant despite high levels of anti-S antibody. Again, it appears that this use of casirivimab/imdevimab was highly effective during the Delta surge, which speaks to the utility of preexposure prophylaxis as a concept in vulnerable patients.…”

Section: Monoclonal Antibodies For Prophylaxismentioning

confidence: 99%

See 1 more Smart Citation

Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge

Avery

2022

Transplantation

View full text Add to dashboard Cite

Major changes have occurred in therapeutics for coronavirus-19 (COVID-19) infection over the past 12–18 mo, most notably in early outpatient therapy. In most cases, solid organ transplant recipients were not included in the original clinical trials of these agents, so studies of real-world outcomes have been important in building our understanding of their utility. This review examines what is known about clinical outcomes in solid organ transplant recipients with newer therapies. SARS-CoV-2 monoclonal antibodies for early treatment or prophylaxis have likely prevented many hospitalizations and deaths. In addition, convalescent plasma, the oral drugs nirmatrelvir/ritonavir and molnupiravir, remdesivir for early outpatient treatment, anti-inflammatory therapy, and investigational virus-specific T-cell therapy will be discussed. Finally, the later consequences of COVID-19, such as secondary infections, long COVID symptoms, and persistent active infection, are identified as areas for future research.

show abstract

Section: Monoclonal Antibodies For Prophylaxismentioning

confidence: 99%

Section: Monoclonal Antibodies For Prophylaxismentioning

confidence: 99%

Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge

Avery

2022

Transplantation

View full text Add to dashboard Cite

show abstract

“…Several groups, including ours, have shown that a monthly dose of casirivimab/imdevimab was highly effective in preventing Delta variant infection [44,71,72]. In a large cohort, no patient developed Delta variant infection, but this combination is not effective against the Omicron variant, both in vitro [73,74] and in vivo [75]. Currently, Evushled ® , a combination of two monoclonal antibodies, Cilgavimab and Tixagevimab, is approved in several countries in this context, and they have recently demonstrated their efficacy in preventing COVID-19 infection [76].…”

Section: Anti-sars-cov2 Neutralizing Monoclonal Antibodiesmentioning

confidence: 79%

Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?

Bello

Marion

Izopet

et al. 2022

Viruses

Self Cite

View full text Add to dashboard Cite

Increased mortality due to SARS-CoV-2 infection was observed among solid organ transplant patients. During the pandemic, in order to prevent and treat COVID-19 infections in this context, several innovative procedures and therapies were initiated within a short period of time. A large number of these innovations can be applied and expanded to improve the management of non-COVID-19 infectious diseases in solid organ transplant patients and in the case of a future pandemic. In this vein, the present paper reviews and discusses medical care system adaptation, modification of immunosuppression, adjuvant innovative therapies, the role of laboratory expertise, and the prevention of infections as examples of such innovations.

show abstract

“…This state of art changed with the advent of the Omicron variants. Kamar et al (53) reported an Omicron breakthrough infection in a KTx patient given pre-exposition casirivimab and imdevimab monoclonal antibodies. The infection occurred despite a high concentration of anti-S antibodies that usually confers a 100% protection against non-Omicron variants.…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

What is New in Prophylaxis and Treatment of Covid- 19 in Renal Transplant Patients?

Salvadori¹

2022

Preprint

View full text Add to dashboard Cite

Kidney transplant recipients, because of a weak immune response due to the assumption of immunosuppressant are exposed to the risk of COVID-19 infection. This fact realize the problem on how to treat the severe infection without carrying the risk of acute rejection due to the reduction of the immunosuppressive drugs. The best are the prophylactic measures to be taken before transplantation as vaccination. If the patient is already transplanted, three measures may be undertaken: Vaccination, use of monoclonal antibodies, use of therapeutic antiviral small molecules. Concerning vaccination is still debated which one is the best and how many doses should be given. The surge of new virus variant is the major problem and invites to find new active vaccines. In addition, not all the transplanted patients develop antibodies. The other measure is the use of monoclonal antibodies. They may be used as prophylaxis or in the early stage of the disease. Finally, the antiviral small molecules may be used again as prophylaxis or treatment. Their major drawback are the interference with the immunosuppressive drugs and the fact that some of them cannot be administered to patients with low eGFR.

show abstract

Omicron breakthrough infection in a kidney‐transplant patient given pre‐exposition casirivimab and imdevimab monoclonal antibodies

Cited by 6 publications

References 10 publications

Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge

Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge

Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?

What is New in Prophylaxis and Treatment of Covid- 19 in Renal Transplant Patients?

Contact Info

Product

Resources

About